Joint Formulary & PAD

Daclatasvir - Hepatitis C

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Red
Formulations :
  • Tablets
Associated Icons :
BNF SPC
NHSE
NICE
R
Restrictions / Comments :

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Daclatasvir
Indication :
Hepatitis C
Group Name :
Keywords :
Hep C, NICE, cirrhosis, fibrosis, peginterferon alfa, ribavirin, sofosbuvir, METAVIR, HCV, hepatitis, antiviral
Brand Names Include :
Daklinza
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0

Other Indications

Below are listed other indications that Daclatasvir is used to treat.

  • No records returned.

Committee Recommendations (1)

Implementation of NICE TA 364 - Daclatasvir is recommended by NICE guidance.

This drug / device falls under the responsibility of NHS England Specialised Commissioning and should therefore not be prescribed in Primary Care.
Treatment should remain with the specialist (RED) hospital only drug.

GPs should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient’s medication.